Published in J Mol Med (Berl) on October 17, 2001
Levels of dipeptidyl peptidase IV/CD26 substrates neuropeptide Y and vasoactive intestinal peptide in rheumatoid arthritis patients. Rheumatol Int (2013) 1.53
Neural immune pathways and their connection to inflammatory diseases. Arthritis Res Ther (2003) 1.40
Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjogren's syndrome. Ann Rheum Dis (2005) 1.20
Neuropeptides rescue mice from lethal sepsis by down-regulating secretion of the late-acting inflammatory mediator high mobility group box 1. Am J Pathol (2008) 1.11
Protective effect of vasoactive intestinal peptide on bone destruction in the collagen-induced arthritis model of rheumatoid arthritis. Arthritis Res Ther (2005) 1.07
Vasoactive intestinal peptide loss leads to impaired CNS parenchymal T-cell infiltration and resistance to experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A (2010) 0.97
Actively targeted low-dose camptothecin as a safe, long-acting, disease-modifying nanomedicine for rheumatoid arthritis. Pharm Res (2010) 0.91
Horizons in Sjögren's syndrome genetics. Clin Rev Allergy Immunol (2007) 0.90
Modulation of T cell immune functions by the prostaglandin E(2) - cAMP pathway in chronic inflammatory states. Br J Pharmacol (2012) 0.85
VIP modulates the pro-inflammatory maternal response, inducing tolerance to trophoblast cells. Br J Pharmacol (2009) 0.84
Endogenous anti-inflammatory neuropeptides and pro-resolving lipid mediators: a new therapeutic approach for immune disorders. J Cell Mol Med (2008) 0.83
Vasoactive intestinal peptide impairs leucocyte migration but fails to modify experimental murine colitis. Clin Exp Immunol (2005) 0.83
Altered vasoactive intestinal peptides expression in irritable bowel syndrome patients and rats with trinitrobenzene sulfonic acid-induced colitis. World J Gastroenterol (2015) 0.83
The absence of the VPAC(2) receptor does not protect mice from Aspergillus induced allergic asthma. Peptides (2010) 0.82
Neural networks in intestinal immunoregulation. Organogenesis (2013) 0.82
Tuning immune tolerance with vasoactive intestinal peptide: a new therapeutic approach for immune disorders. Peptides (2007) 0.81
Clinical Relevance of VPAC1 Receptor Expression in Early Arthritis: Association with IL-6 and Disease Activity. PLoS One (2016) 0.80
Proliferative enteropathy (PE)-induced changes in the calbindin-immunoreactive (CB-IR) neurons of inferior mesenteric ganglion supplying the descending colon in the pig. J Mol Neurosci (2011) 0.80
Vasoactive intestinal peptide-deficient mice exhibit reduced pathology in trinitrobenzene sulfonic acid-induced colitis. Neuroimmunomodulation (2014) 0.80
Prospect of vasoactive intestinal peptide therapy for COPD/PAH and asthma: a review. Respir Res (2011) 0.79
Nanomedicine: evolutionary and revolutionary developments in the treatment of certain inflammatory diseases. Inflamm Res (2011) 0.78
Secretion of immunomodulating neuropeptides (VIP, SP) and nitric oxide synthase in porcine small intestine during postnatal development. Eur J Histochem (2012) 0.78
Modulatory effects of vasoactive intestinal peptide on intestinal mucosal immunity and microbial community of weaned piglets challenged by an enterotoxigenic Escherichia coli (K88). PLoS One (2014) 0.78
Defects in the vasoactive intestinal peptide (VIP)/VPAC system during early stages of the placental-maternal leucocyte interaction impair the maternal tolerogenic response. Clin Exp Immunol (2012) 0.76
Nanomedicine delivers promising treatments for rheumatoid arthritis. Nanomedicine (Lond) (2015) 0.75
Expression and localization of VPAC1, the major receptor of vasoactive intestinal peptide along the length of the intestine. Am J Physiol Gastrointest Liver Physiol (2017) 0.75
General and abdominal adiposity and risk of death in Europe. N Engl J Med (2008) 14.49
Randomized study comparing the "sniffing position" with simple head extension for laryngoscopic view in elective surgery patients. Anesthesiology (2001) 6.19
Separating the retinal electrophysiologic effects of vigabatrin: treatment versus field loss. Neurology (2000) 2.90
Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med (2001) 2.81
Repeated stress causes reversible impairments of spatial memory performance. Brain Res (1994) 2.55
Interfacial activation of the lipase-procolipase complex by mixed micelles revealed by X-ray crystallography. Nature (1993) 2.00
Insulin increases the association of Akt-2 with Glut4-containing vesicles. J Biol Chem (1998) 1.95
The multicentre south European study 'Helios'. II: Different sun exposure patterns in the aetiology of basal cell and squamous cell carcinomas of the skin. Br J Cancer (1996) 1.61
DNA repair polymorphisms and cancer risk in non-smokers in a cohort study. Carcinogenesis (2005) 1.54
Alkaline and neutral Comet assay profiles of sperm DNA damage in clinical groups. Hum Reprod (2012) 1.52
Neurobehavioral outcomes in preterm, growth-restricted infants with and without prenatal advanced signs of brain-sparing. Ultrasound Obstet Gynecol (2011) 1.51
Characteristics of a unique visual field defect attributed to vigabatrin. Epilepsia (1999) 1.50
Use of dietary supplements in the European Prospective Investigation into Cancer and Nutrition calibration study. Eur J Clin Nutr (2009) 1.49
Low section of the rectum during laparoscopic total mesorectal excision using the Contour device. Technical report. Surg Endosc (2006) 1.48
QTL mapping of grain quality traits from the interspecific cross Oryza sativa x O. glaberrima. Theor Appl Genet (2004) 1.48
Risk factors for acquisition of urinary tract infections caused by ciprofloxacin resistant Escherichia coli. J Urol (1995) 1.44
Postthymectomy wasting associated with autoimmune phenomena. I. Antiglobulin-positive anemia in A and C57BL-6 Ks mice. J Exp Med (1967) 1.44
Low IgG2 and polysaccharide response in a T cell receptor expression defect. Eur J Immunol (1990) 1.43
Folk diseases among urban Mexican-Americans. Etiology, symptoms, and treatment. JAMA (1966) 1.41
Pulmonary arterial hypertension and cor pulmonale associated with chronic domestic woodsmoke inhalation. Chest (1993) 1.41
Gastrointestinal dysfunction in mice with a targeted mutation in the gene encoding vasoactive intestinal polypeptide: a model for the study of intestinal ileus and Hirschsprung's disease. Peptides (2007) 1.36
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies. J Immunol (1999) 1.35
The development and function of gamma delta T cells. Immunol Today (1990) 1.33
Recovery from autoimmunity of MRL/lpr mice after infection with an interleukin-2/vaccinia recombinant virus. Nature (1990) 1.33
Balloon-expandable stent repair of severe coarctation of aorta. Am Heart J (1995) 1.29
Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activation polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-alpha and IL-6. J Immunol (1999) 1.26
Restraint stress reversibly enhances spatial memory performance. Physiol Behav (1996) 1.25
The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden. Blood (2001) 1.24
The immunologic competence of mouse thymus cells measured by the graft vs. host spleen assay. J Immunol (1966) 1.21
Functionally distinct subsets of human gamma/delta T cells. Eur J Immunol (1991) 1.21
Pneumonia due to Bordetella bronchiseptica in a patient with AIDS. Rev Infect Dis (1991) 1.21
Analysis of genetic variability and mapping of point mutations in influenza virus by the RNase A mismatch cleavage method. Proc Natl Acad Sci U S A (1988) 1.21
Prevention of endemic healthcare-associated Clostridium difficile infection: reviewing the evidence. Am J Gastroenterol (2010) 1.20
Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy. Clin Endocrinol (Oxf) (1996) 1.19
Interleukin 2 promotes growth and cytolytic activity in human T3+4-8- thymocytes. Proc Natl Acad Sci U S A (1985) 1.19
Mapping of genes controlling aluminum tolerance in rice: comparison of different genetic backgrounds. Mol Genet Genomics (2002) 1.18
Manganese intoxication and chronic liver failure. Ann Neurol (1994) 1.18
The multicentre south European study 'Helios'. I: Skin characteristics and sunburns in basal cell and squamous cell carcinomas of the skin. Br J Cancer (1996) 1.17
Regulation of VIP production and secretion by murine lymphocytes. J Neuroimmunol (1999) 1.15
Mobilization of potent plasma bactericidal activity during systemic bacterial challenge. Role of group IIA phospholipase A2. J Clin Invest (1998) 1.15
A suggested mechanism for T lymphocyte activation: implications on the acquisition of functional reactivities. Immunol Rev (1980) 1.15
Two basic residues of the h-VPAC1 receptor second transmembrane helix are essential for ligand binding and signal transduction. J Biol Chem (2001) 1.14
Inducible binding of cyclic adenosine 3',5'-monophosphate (cAMP)-responsive element binding protein (CREB) to a cAMP-responsive promoter in vivo. Mol Endocrinol (1999) 1.10
Diet, serum insulin-like growth factor-I and IGF-binding protein-3 in European women. Eur J Clin Nutr (2006) 1.10
VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNgamma synthesis by T cells. J Neuroimmunol (1999) 1.09
Comparison of risk patterns in carcinoma and melanoma of the skin in men: a multi-centre case-case-control study. Br J Cancer (2006) 1.08
Dynamics of indigenous yeast populations during spontaneous fermentation of wines from Mendoza, Argentina. Int J Food Microbiol (2005) 1.08
Dynamics of Fusarium solani cutinase investigated through structural comparison among different crystal forms of its variants. Proteins (1996) 1.07
Cardiac hemangioma. Ann Thorac Surg (1994) 1.07
Multicenter prospective study of treatment of Brucella melitensis brucellosis with doxycycline for 6 weeks plus streptomycin for 2 weeks. Antimicrob Agents Chemother (1990) 1.07
Thymic stroma is required for the development of human T cell lineages in vitro. Int Immunol (1989) 1.07
Microphthalmos with cyst: clinical presentations and computed tomographic findings. J Pediatr Ophthalmol Strabismus (1985) 1.07
Impaired nerve regeneration and enhanced neuroinflammatory response in mice lacking pituitary adenylyl cyclase activating peptide. Neuroscience (2007) 1.06
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit endotoxin-induced TNF-alpha production by macrophages: in vitro and in vivo studies. J Immunol (1999) 1.06
Differential expression of vasoactive intestinal peptide receptors 1 and 2 (VIP-R1 and VIP-R2) mRNA in murine lymphocytes. J Neuroimmunol (1996) 1.06
Assessment of the debrisoquin and dextromethorphan phenotyping tests by gaussian mixture distributions analysis. Clin Pharmacol Ther (1989) 1.05
Genetic susceptibility according to three metabolic pathways in cancers of the lung and bladder and in myeloid leukemias in nonsmokers. Ann Oncol (2007) 1.05
Blood manganese correlates with brain magnetic resonance imaging changes in patients with liver disease. Can J Neurol Sci (1996) 1.04
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide modulate endotoxin-induced IL-6 production by murine peritoneal macrophages. J Leukoc Biol (1998) 1.04
Anatomy of the gonadal veins: a reappraisal. Surgery (1991) 1.04
Nerve root prolapse into a spinal arachnoid cyst--an unusual cause of radiculopathy. Clin Neurol Neurosurg (2009) 1.03
VIP-PACAP system in immunity: new insights for multitarget therapy. Ann N Y Acad Sci (2006) 1.03
[Tuberculosis and diabetes mellitus: a longitudinal-retrospective study in a teaching hospital]. Rev Med Chil (1989) 1.03
Anti-inflammatory properties of the type 1 and type 2 vasoactive intestinal peptide receptors: role in lethal endotoxic shock. Eur J Immunol (2000) 1.02
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide stimulate the induction of Th2 responses by up-regulating B7.2 expression. J Immunol (1999) 1.02
Establishment of idiotypic helper T-cell repertoires early in life. Nature (1985) 1.02
Immunology of VIP: a review and therapeutical perspectives. Curr Pharm Des (2001) 1.02
Fruits and vegetables consumption and the risk of histological subtypes of lung cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Causes Control (2010) 1.02
Alcohol intake and the risk of coronary heart disease in the Spanish EPIC cohort study. Heart (2009) 1.02
Induction of neuropeptide gene expression and blockade of retrograde transport in facial motor neurons following local peripheral nerve inflammation in severe combined immunodeficiency and BALB/C mice. Neuroscience (2004) 1.02
VIP down-regulates TLR4 expression and TLR4-mediated chemokine production in human rheumatoid synovial fibroblasts. Rheumatology (Oxford) (2005) 1.01
Immunobiology of vasoactive intestinal peptide (VIP) Immunol Today (2000) 1.01
Multi-factor dimensionality reduction applied to a large prospective investigation on gene-gene and gene-environment interactions. Carcinogenesis (2006) 1.01
El hospital invisible. A study of Curanderismo. Arch Gen Psychiatry (1977) 1.01
Anatomo-radiological study of the Superior Semicircular Canal Dehiscence Radiological considerations of Superior and Posterior Semicircular Canals. Eur J Radiol (2009) 1.00